专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

KR1020140045894A 개머루덩굴 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 유효성분으로 포함하는 ＩＬ-6 매개성 질환의 예방 또는 치료용 약학적 조성물 有权
标题翻译：用于预防或治疗IL-6介导性疾病的药物组合物，包括从AMPELOPSIS BREVIPEDUNCULATA衍生的提取物，分离物或化合物
公开(公告)号：KR1020140045894A
公开(公告)日：2014-04-17
申请号：KR1020130120106
申请日：2013-10-08
申请人： 한국생명공학연구원
发明人： 노문철 , 이승웅 , 오현미 , 오재민 , 이우송 , 박찬선 , 이명수
IPC分类号： A61K36/87 , A61K31/045 , A61K31/35 , A61P35/00 , A61P19/02 , A61P29/00
CPC分类号： A61K31/216 , A23L2/52 , A23L29/035 , A61K31/192 , A61K36/87 , A61K2236/33 , A61K2236/35 , Y10S424/81 , Y10S514/825 , Y10S514/886
摘要： The present invention relates to a pharmaceutical composition for preventing or treating interleukin-6 (IL-6) mediated diseases and a method for treating IL-6 mediated diseases, which comprises the step of administering the composition to a subject suspected to have IL-6 mediated diseases, wherein the composition comprises an Ampelopsis brevipedunculata extract, a fraction thereof, or a compound isolated therefrom or a pharmaceutically acceptable salt thereof as an active ingredient. Further, the present invention relates to a food composition, a quasi-drug composition, a feed additive, and a drink additive comprising an Ampelopsis brevipedunculata extract, a fraction thereof, or a compound isolated therefrom or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or alleviating IL-6 mediated diseases.
摘要翻译：本发明涉及用于预防或治疗白细胞介素-6（IL-6）介导的疾病的药物组合物和治疗IL-6介导的疾病的方法，其包括向怀疑患有IL-6的受试者施用组合物的步骤其中所述组合物包含短叶黄连提取物，其分数或从其分离的化合物或其药学上可接受的盐作为活性成分。此外，本发明涉及一种食品组合物，准药物组合物，饲料添加剂和饮料添加剂，其特征在于，所述食品组合物包含短叶甜菜提取物，其分数或从其分离的化合物或其药学上可接受的盐作为活性成分用于预防或减轻IL-6介导的疾病。

42. 发明公开

KR1020140020685A 신규한 락토코쿠스 종 균주 및 이의 용도 有权
标题翻译：一个新的LACTOCOCCUS SP。应变和使用
公开(公告)号：KR1020140020685A
公开(公告)日：2014-02-19
申请号：KR1020120088050
申请日：2012-08-10
申请人： 한국생명공학연구원
发明人： 노문철 , 박찬선 , 이우송 , 이승웅 , 오현미
IPC分类号： C12N1/20 , A61K35/74 , A23K1/16
摘要： The present invention provides Lactococcus sp. KR-050L which is a novel strain and described in deposit number of KCTC 12170BP; a pharmaceutical composition for preventing or treating cancer or inflammatory diseases which includes Lactococcus sp. KR-050L culture medium, fungus body, or supernatant, extracts thereof, or fractions thereof as effective components; a composition for inhibiting activities for signal transducers and activators of transcription 3 (STAT3) which is induced by interleukin-6 (IL-6) or IL-11 which includes Lactococcus sp. KR-050L culture medium, Lactococcus sp. KR-050L fungus body, or supernatant, extracts thereof, or fractions thereof; foods, food additive, forage, or forage additive which includes the Lactococcus sp. KR-050L or the culture medium thereof; and personal hygienic goods which includes the Lactococcussp. KR-050L or culture thereof.
摘要翻译：本发明提供了乳球菌属 KR-050L是一种新型菌株，以KCTC 12170BP的保藏号记载; 用于预防或治疗癌症或炎性疾病的药物组合物，其包括乳球菌属 KR-050L培养基，真菌体或上清液，其提取物或其部分作为有效成分; 用于抑制白细胞介素-6（IL-6）或IL-11诱导的信号转导和转录激活因子3（STAT3）活性的组合物，其包括乳球菌属 KR-050L培养基，乳球菌属 KR-050L真菌体，或上清液，其提取物或其级分; 食品，食品添加剂，饲料或包含乳球菌属的饲料添加剂。 KR-050L或其培养基; 以及包括乳酸菌在内的个人卫生用品。 KR-050L或其培养物。

43. 发明授权

KR101350954B1 아실-코에이:콜레스테롤 아실 트랜스퍼라제 저해 활성을가지는 조성물 有权
标题翻译：用于抑制酰基辅酶A的组合物：胆固醇酰基转移酶
公开(公告)号：KR101350954B1
公开(公告)日：2014-01-23
申请号：KR1020060064138
申请日：2006-07-08
申请人： 한국생명공학연구원
发明人： 김영국 , 노문철 , 이현선 , 이승웅 , 권오억 , 정미연 , 최정호 , 동미숙
IPC分类号： A61K36/67 , A61P3/06
CPC分类号： A61K31/4453 , A61K31/357 , A61K36/67
摘要： 본 발명은 호초(Piper nigrum L.) 추출물 또는 그로부터 분리된 래트로프렉트아마이드 에이(ractamideRetrof A), 피퍼사이드(pipercide), 피페롤레인 비(piperolein B), 피퍼차바미드 디(piperchabamide D) 및 펠리토린(pellitorine)으로 이루어진 그룹중에서 선택되는 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해 활성을 가지는 조성물에 관한 것으로, 상기 조성물은 고지혈증, 동맥경화 등의 혈관 질환에 대한 예방 및 치료 효과를 가진다.
아실-코에이:콜레스테롤 아실 트랜스퍼라제(acyl-CoA:cholesterolacyltransferase, ACAT), 고콜레스테롤혈증, 아마이드(amide), 피퍼사이드(Pipercide), 호초(Piper nigrum L.)

44. 发明授权

KR101271562B1 올레아놀린산 아세테이트를 포함하는 자가면역질환 예방 또는 치료용 약학적 조성물 有权
标题翻译：一种包含齐墩果酸乙酸酯用于预防或治疗自身免疫性疾病的药物组合物
公开(公告)号：KR101271562B1
公开(公告)日：2013-06-11
申请号：KR1020120012051
申请日：2012-02-06
申请人： 한국생명공학연구원
发明人： 노문철 , 오현미 , 이우송 , 이승웅 , 박수진 , 김영민 , 류영배
IPC分类号： A61K31/56 , A61P19/10 , A61P19/00
CPC分类号： A61K36/48 , A61K31/56
摘要： 올레아놀린산 아세테이트(oleanolic acid acetate), 이의 약학적으로 허용되는 염, 상기 올레아놀린산 아세테이트를 포함하는 적소두 추출물 또는 상기 올레아놀린산 아세테이트를 포함하는 적소두 추출물의 분획물을 유효성분으로 포함하는 TLR 및 IL-6 매개성 질환의 예방 또는 치료용 약학적 조성물, 상기 조성물을 포함하는 피부 외용제, 건강기능식품 및 개인위생용품에 관한 것이다. 본 발명의 적소두 추출물 또는 화합물은 오랫동안 천연약재로서 사용되어온 천연물에서 유래되어 부작용이 없으면서도, dsRNA 및 ssRNA의 합성 유사체인 Poly(I:C)와 Poly(I)에 의해 유도되는 TLR-3 및 TLR-7의 활성저해 및 NF-κB를 포함하는 신호전달 경로를 차단하고, IL-6에 의해 활성화되는 염증관련 전사인자인 STAT3의 전사활성 및 인산화 저해 및 DNCB에 의한 NC/Nga 마우스의 아토피성 피부염의 유발을 억제할 수 있으므로, 다양한 TLR 및 IL-6 매개성 질환의 예방 또는 치료제의 개발에 널리 활용될 수 있을 것이다.

45. 发明公开

KR1020130014227A 신규한 α-글루코실 스테비오사이드 및 이의 제조 방법 无效
标题翻译：新型α-GLUCOSYL STEVIOSIDES及其生产方法
公开(公告)号：KR1020130014227A
公开(公告)日：2013-02-07
申请号：KR1020110076211
申请日：2011-07-29
申请人： 한국생명공학연구원
发明人： 이우송 , 김영민 , 노문철 , 류영배 , 박수진 , 김중수
IPC分类号： C07H7/04 , C07H15/24 , C07H1/08 , C12P19/16 , C12P19/56 , C12N9/10 , A23L27/30
CPC分类号： C07H15/24 , A23L27/36 , C12P19/56 , C07H7/04 , A23L27/33 , C07H1/08 , C07H7/00 , C12N9/1051 , C12N9/14 , C12P19/00 , C12P19/16 , C12Y204/01005
摘要： PURPOSE: A method for preparing a novel alpha-glucosyl stevioside is provided to obtain the novel alpha-glucosyl stevioside with high yield and to improve sweetness thereof. CONSTITUTION: An alpha-glucosyl stevioside has glucose which is linked at 19-OH site of stevioside by an alpha-glycoside bond. The glycosyl stevioside is denoted by chemical formula 1 or 2. A method for preparing the alpha-glucosyl stevioside comprises a step of treating stevioside with glucansucrase or a microorganism which produces glucansucrase. The glucansucrase is derived from Leuconostoc sp. An alpha-glycosylation composition of stevioside contains sucrose and glucansucrase or the microorganism which produces glucansucrase.
摘要翻译：目的：提供一种制备新型α-葡萄糖基甜菊苷的方法，以高产率获得新型α-葡萄糖甜菊苷，并改善甜味。构成：α-葡萄糖基甜菊糖苷具有通过α-糖苷键在甜菊苷的19-OH位点连接的葡萄糖。糖苷甜菊苷由化学式1或2表示。制备α-葡糖基甜菊苷的方法包括用葡聚糖蔗糖酶或产生葡聚糖蔗糖酶的微生物处理甜菊苷的步骤。葡聚糖蔗糖酶来源于明串珠菌甜菊糖苷的α-糖基化组合物含有蔗糖和葡聚糖蔗糖酶或产生葡聚糖蔗糖酶的微生物。

46. 发明公开

KR1020110086473A 감태 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물 및 3ＣＬ 프로테아제 활성의 억제용 조성물 无效
标题翻译：用于预防或治疗冠状病毒感染的组合物和用于抑制包含ECKLONIA CAVA的3C样蛋白的活性的组合物
公开(公告)号：KR1020110086473A
公开(公告)日：2011-07-28
申请号：KR1020100006227
申请日：2010-01-22
申请人： 한국생명공학연구원
发明人： 이우송 , 노문철 , 류영배 , 박수진 , 장종선 , 권형준 , 김하현 , 정형재
IPC分类号： A61K36/03 , A61P31/12
CPC分类号： A61K36/03 , A23L33/00
摘要： PURPOSE: A composition containing Ecklonia cava extract or fraction of the extract for preventing or treating coronaviral infection is provided to suppress 3CL protease activity. CONSTITUTION: A composition for preventing or treating coronaviral infection contains Ecklonia cava extract or fraction of the extract as an active ingredient. The extract is isolated using water, alcohol of C1-C4, or mixture solvent thereof. The fraction is a hexane fraction, ethyl acetate fraction, or water fraction. The composition is a pharmaceutical or food composition. The pharmaceutical composition is manufactured in the form of tablet, pill, powder, granule, capsule, suspension, emulsion, syrup, non-aqueous solvent, suspension, or suppository. A composition for suppressing 3CL protease activity contains the extract or fraction of the extract as an active ingredient.
摘要翻译：目的：提供含有Ecklonia cava提取物或提取物级分用于预防或治疗冠状病毒感染的组合物以抑制3CL蛋白酶活性。构成：用于预防或治疗冠状病毒感染的组合物含有Ecklonia cava提取物或提取物的级分作为活性成分。使用水，C1-C4的醇或其混合溶剂分离提取物。馏分是己烷馏分，乙酸乙酯馏分或水馏分。组合物是药物或食物组合物。药物组合物以片剂，丸剂，粉末，颗粒剂，胶囊剂，悬浮液，乳剂，糖浆剂，非水溶剂，悬浮液或栓剂的形式制备。用于抑制3CL蛋白酶活性的组合物含有提取物的提取物或级分作为活性成分。

47. 发明公开

KR1020110061883A 트리터페노이드계 사포닌 화합물을 포함하는 염증성 질환의 예방 및 치료용 약학 조성물 无效
标题翻译：用于治疗和预防包含三磷酸肌苷酸化合物的炎症疾病的药物组合物
公开(公告)号：KR1020110061883A
公开(公告)日：2011-06-10
申请号：KR1020090118418
申请日：2009-12-02
申请人： 한국생명공학연구원
发明人： 노문철 , 이우송 , 이승웅 , 장종선 , 박수진 , 류영배 , 김민석
IPC分类号： A61K36/233 , A61P29/00 , A61K31/7048
CPC分类号： Y02A50/411 , A61K36/233 , A61K31/7048 , A61K2236/33 , A61K2236/55 , Y10S424/81 , Y10S514/824 , Y10S514/825 , Y10S514/826 , Y10S514/866 , Y10S514/886
摘要： PURPOSE: A pharmaceutical composition containing Bupleurum falcatum extract or triterpenoid saponin compounds is provided to suppress VCAM-1 and VLA-4-mediated cell adhesion and to prevent and treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains Bupleurum falcatum extract or fraction thereof as an active ingredient. The extract is isolated using water, low alcohol of 1-4 carbon atoms, or mixture solvent thereof. The fraction is water, n-hexane, or chloroform fraction. The pharmaceutical composition also contains triterpenoid saponin compounds of chemical formula 1 or 2 as an active ingredient.
摘要翻译：目的：提供含有柴胡提取物或三萜皂苷化合物的药物组合物，以抑制VCAM-1和VLA-4介导的细胞粘附并预防和治疗炎性疾病。构成：用于预防或治疗炎性疾病的药物组合物含有柴胡提取物或其馏分作为活性成分。使用水，1-4个碳原子的低级醇或其混合溶剂分离提取物。该馏分是水，正己烷或氯仿馏分。药物组合物还含有化学式1或2的三萜皂苷化合物作为活性成分。

48. 发明公开

KR1020110057010A 폴리페놀성 화합물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 有权
标题翻译：用于预防和治疗流感病毒和组合物的组合物，用于抑制包含聚苯酚化合物的神经酰胺糖苷酶的活性
公开(公告)号：KR1020110057010A
公开(公告)日：2011-05-31
申请号：KR1020090113538
申请日：2009-11-23
申请人： 한국생명공학연구원
发明人： 이우송 , 노문철 , 박수진 , 류영배 , 장종선 , 정형재 , 권형준 , 김하현
IPC分类号： A61K31/121 , A61P31/16 , A61K31/7034 , A61K31/7042
摘要： PURPOSE: A pharmaceutical composition containing polyphenolic compounds such as chalcones or flavonoids is provided to prevent or treat influenza viral infection. CONSTITUTION: A composition for preventing and treating influenza viral infection contains a compound of chemical formula 1. The diseases caused by influenza viral infection include flu, pharyngolaryngitis, bronchitis, and pneumonia. The composition is a pharmaceutical, food, or external use product. The pharmaceutical composition is selected from the group consisting of tablet, pill, powder, capsule, suspension, emulsion, syrup, sterilized solution, and suppository.
摘要翻译：目的：提供含有多酚化合物如查尔酮或类黄酮的药物组合物，用于预防或治疗流感病毒感染。构成：用于预防和治疗流感病毒感染的组合物含有化学式1的化合物。由流感病毒感染引起的疾病包括流感，咽喉炎，支气管炎和肺炎。组合物是制药，食品或外用产品。药物组合物选自片剂，丸剂，粉剂，胶囊，悬浮液，乳剂，糖浆，灭菌溶液和栓剂。

49. 发明公开

KR1020110011968A 오수유 추출물, 이의 분획물 또는 퀴놀론 알칼로이드계 화합물을 포함하는 약학 조성물 有权
标题翻译：包含EVODIA FRUCTUS或QUINOLONE ALKALOID化合物的提取物或分离物的药物组合物
公开(公告)号：KR1020110011968A
公开(公告)日：2011-02-09
申请号：KR1020090069469
申请日：2009-07-29
申请人： 한국생명공학연구원
发明人： 노문철 , 이우송 , 이승웅 , 장종선 , 박수진 , 김민수 , 류영배 , 임주환
IPC分类号： A61K36/754 , A61K31/122 , A23L1/30 , A61P31/16
CPC分类号： Y02A50/411 , A61K31/438 , A23L29/035 , A61K36/754 , Y10S424/81 , Y10S514/825 , Y10S514/857 , Y10S514/866 , Y10S514/886 , Y10S514/912 , Y10S514/925
摘要： PURPOSE: A pharmaceutical composition containing quinolone alkaloid compounds derived from Evodia fructus for preventing and treating inflammatory diseases or infectious diseases is provided to suppress binding between ICAM-1 and LFA-1(CD11a/CD18). CONSTITUTION: A composition for preventing or treating common cold contains Evodia fructus extract, fraction thereof, or compound of chemical formula 1-4. An external use skin formulation contains the composition. The external use skin formulation is used in the form of ointments, lotions, sprays, patchs, creams, powders, suspensions, or gels. A food product contains the composition. A pharmaceutical composition for preventing or treating inflammatory diseases or infectious diseases contains a compound of chemical formula 3 or 4 as an active ingredient. The compound of chemical formula 3 or 4 is isolated from Evodia fructus.
摘要翻译：目的：提供一种含有用于预防和治疗炎症性疾病或感染性疾病的抗逆转录病毒的喹诺酮生物碱化合物的药物组合物，以抑制ICAM-1和LFA-1（CD11a / CD18）之间的结合。构成：用于预防或治疗普通感冒的组合物含有Evodia fructus提取物，其馏分或化学式1-4的化合物。外用皮肤制剂含有组合物。外用皮肤制剂以软膏，洗剂，喷雾剂，贴剂，霜剂，粉剂，混悬剂或凝胶的形式使用。食品中含有组合物。用于预防或治疗炎性疾病或感染性疾病的药物组合物含有化学式3或4的化合物作为活性成分。化学式3或4的化合物与Evodia fructus分离。

50. 发明公开

KR1020090032600A 필발로부터 분리된 세포접착저해 물질을 유효성분으로 하는염증성 질환 의 예방 및 치료용 조성물 有权
标题翻译：包含来自管壁分离的细胞粘附分子的抑制剂的药物组合物用于预防和治疗炎症疾病
公开(公告)号：KR1020090032600A
公开(公告)日：2009-04-01
申请号：KR1020070097967
申请日：2007-09-28
申请人： 한국생명공학연구원
发明人： 노문철 , 김영국 , 이현선 , 전창덕 , 김관회 , 이승웅 , 최정호 , 송재준
IPC分类号： A61K36/67 , A61P31/00
CPC分类号： A61K36/67 , Y10S514/825 , Y10S514/826 , Y10S514/857 , Y10S514/866 , Y10S514/886 , Y10S514/925
摘要： A pharmaceutical composition containing Piper longum extracts and amide-based compounds extracted from the Piper longum is provided to suppress endothelial cell adhesion and penetration by inhibiting ICAM-1(Intercellular adhesion molecule-1) and LFA-1(Leukocyte function associated antigen-1)-mediated cell adhesion. A pharmaceutical composition for treatment of inflammatory diseases comprises Piper longum extracts, which is obtained by water, C1-C4 low alcohol or mixed solvents thereof. The inflammatory diseases indicate diseases caused by rhinovirus or HIV-1(Human immunodeficiency virus). The pharmaceutical composition for treatment of inflammatory diseases contains each compound represented by the formula 1 to 4 or one of compounds represented by the formula 1 to 4.
摘要翻译：提供了含有琵琶长叶提取物和从per龙提取的酰胺类化合物的药物组合物，通过抑制ICAM-1（细胞间粘附分子-1）和LFA-1（白细胞功能相关抗原-1）抑制内皮细胞粘附和渗透，介导的细胞粘附。用于治疗炎性疾病的药物组合物包括通过水，C1-C4低级醇或其混合溶剂获得的Pi子提取物。炎症性疾病是由鼻病毒或HIV-1（人类免疫缺陷病毒）引起的疾病。用于治疗炎性疾病的药物组合物含有由式1至4表示的每种化合物或由式1至4表示的化合物之一。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式